OM

Outset's Tablo hemodialysis story has a real bright spot: the loss trajectory is finally bending the right way. Gross profit grew +21.2% to $46.8M (39.1% margin) on only +5.1% revenue growth, net loss narrowed 36% to -$81.7M, and operating cash burn improved 60% to -$46.3M. Management's MD&A is explicitly built around the right levers — selling more recurring Tablo cartridges/service (now 45%+29% of revenue vs 26% consoles) and cutting console/service cost to expand gross margin. R&D was slashed 44.7% to $21.2M, consistent with the restructuring they cite. The mix shift toward high-margin recurring revenue is the legitimate bull case here.

But the balance sheet overrides the operating progress. Cash & equivalents collapsed 71.8% to just $35.0M, while the company still burned $46.3M from operations last year — that is less than one year of runway at the current pace. The 66% drop in share count (18.3M shares) signals a reverse split, and stockholders' equity jumping +373% points to a recent dilutive raise/restructuring already executed; with $96.2M of long-term debt still on the books and a -$1.17B accumulated deficit, the company is structurally dependent on capital markets. At a $79.3M market cap, any new equity raise is brutally dilutive, and the MD&A's repeated language about 'cash use, cash burn and cash position' and 'sufficiency of our capital resources' is the tell.